TY  - BOOK
AU  - Serzan, Michael
TI  - Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab
SN  - 1473-7140
PY  - 2022///
KW  - IN PROCESS -- NOT YET INDEXED
KW  - Hematology & Oncology Fellowship
KW  - MedStar Georgetown University Hospital/MedStar Washington Hospital Center
KW  - Journal Article
N2  - AREAS COVERED: We provide an overview of efforts to develop an adjuvant therapy in patients with high-risk RCC. This includes a critical review of efficacy, toxicity, and clinical implications from a large phase III trial leading to the FDA and EMA approvals of adjuvant pembrolizumab; EXPERT OPINION: Pembrolizumab offers an effective and well-tolerated adjuvant therapy for patients with surgically resected RCC at high-risk of disease recurrence. Future research will focus on optimal patient selection and biomarkers that predict benefit and/or toxicity from therapy; INTRODUCTION: Many patients with renal cell carcinoma (RCC) who undergo surgery with curative intent have a high risk of disease recurrence and until recently no palatable adjuvant systemic therapy options. Blocking the programmed death ligand (PD-1) immune checkpoint pathway with pembrolizumab has robust clinical efficacy in patients with metastatic RCC. Results from the KEYNOTE 564 trial demonstrate that adjuvant pembrolizumab significantly improves disease- free survival after nephrectomy or metastasectomy
UR  - https://dx.doi.org/10.1080/14737140.2022.2072300
ER  -